Last reviewed · How we verify

NCT02029989

Can Point-of-care Testing (POCT) and Assistance From Comprehensive Medication Management (CMM) Pharmacists Improve Early Detection and Management of Metabolic Syndrome in Patients Treated With Antipsychotic Medications?

Completed NA Results posted Last updated 2 April 2024
What this trial tests

NA trial testing Glucose and lipids in Hyperlipidemia in 121 participants. Completed in 1 February 2012.

Timeline
1 February 2010
Primary endpoint
1 February 2012
1 February 2012

Quick facts

Lead sponsorUniversity of Minnesota
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposescreening
Enrollment121
Start date1 February 2010
Primary completion1 February 2012
Estimated completion1 February 2012
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Minnesota

Who can join

Adults 18 to 64, any sex, with Hyperlipidemia or Diabetes. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome. Subjects were also randomized to either an Extended Treatment Group (ETG) defined by receiving comprehensive medication management (CMM) pharmacist interventions or a Usual Treatment Group (UTG) receiving no CMM interventions. All subjects were recruited from three community mental health clinic settings in Minnesota.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Self management interventions for type 2 diabetes in adult people with severe mental illness.
    McBain H, Mulligan K, Haddad M, Flood C, et al · · 2016 · cited 34× · PMID 27120555 · DOI 10.1002/14651858.cd011361.pub2
  2. Twelve-month prospective randomized study of pharmacists utilizing point-of-care testing for metabolic syndrome and related conditions in subjects prescribed antipsychotics.
    Schneiderhan ME, Shuster SM, Davey CS. · · 2014 · cited 11× · PMID 25667811 · DOI 10.4088/pcc.14m01669
  3. Observed Sex Differences in Cardiometabolic Indices in Patients on Antipsychotics: Secondary Analyses of a 12-Month Multicenter, Randomized, Controlled Trial.
    Schneiderhan ME, Li X. · · 2021 · PMID 34000112 · DOI 10.4088/pcc.19m02493

Verify or expand the search:

Other recruiting trials for Hyperlipidemia

Currently open trials in the same condition.

Other University of Minnesota trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02029989.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing